Subsequent loss-of-function mutations or deletions in tumor suppressor genes, such as TP53, SMAD4, and CDKN2A, cooperate with KRAS mutation to drive tumor formation and further exacerbate the disease progression (Figure 1) [6,7]. Here, KRAS is linked to neoplasm.